Nymox Pharmaceutical Corporation (NYMX)
USD 0.2
(-0.05%)
USD 0.2
(-0.05%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.2 Million | -9.82 Million | -10.03 Million | -7.43 Million | -7.8 Million | -6.2 Million |
| Net Income | -6.57 Million | -12.53 Million | -11.73 Million | -13.16 Million | -10.59 Million | -13.42 Million |
| Depreciation & Amortization | 249 Thousand | 254 Thousand | 267 Thousand | 565 Thousand | 3000.00 | 1000.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 593 Thousand | 2.6 Million | 1.74 Million | 3.01 Million | 3.81 Million | 6.29 Million |
| Change in working capital | 495 Thousand | -140 Thousand | -314 Thousand | 826 Thousand | -1.12 Million | 773 Thousand |
| Other non-cash items | 34 Thousand | - | - | 1.33 Million | 101 Thousand | 152 Thousand |
| Investing Cash Flow | - | -6000.00 | -13 Thousand | - | -36 Thousand | - |
| Investments in PPE | - | -6000.00 | -13 Thousand | - | -36 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 5.77 Million | 7.04 Million | 8.42 Million | 4.72 Million | 14.93 Million | 5.03 Million |
| Debt repayment | -229 Thousand | -238 Thousand | -265 Thousand | -277 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 6 Million | 7.28 Million | 8.68 Million | 5 Million | 14.93 Million | 5.03 Million |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | 73 Thousand | -77 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | -11 Thousand | 17 Thousand | -25 Thousand | -13 Thousand |
| Other working capital | - | - | -303 Thousand | 809 Thousand | -1.17 Million | 863 Thousand |
| Cash at beginning of period | 830 Thousand | 3.61 Million | 5.23 Million | 7.94 Million | 851 Thousand | 2.01 Million |
| Cash at end of period | 1.4 Million | 830 Thousand | 3.61 Million | 5.23 Million | 7.94 Million | 851 Thousand |
| Capital Expenditure | - | -6000.00 | -13 Thousand | - | -36 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 573 Thousand | -2.78 Million | -1.62 Million | -2.7 Million | 7.09 Million | -1.16 Million |
| Free Cash Flow | -5.2 Million | -9.82 Million | -10.05 Million | -7.43 Million | -7.83 Million | -6.2 Million |
| Breakdown | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 | 2022 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.11 Million | -1.38 Million | -1.33 Million | -6.57 Million | -1.49 Million | 1.34 Million |
| Depreciation & Amortization | 58 Thousand | 59 Thousand | 61 Thousand | 249 Thousand | 61 Thousand | 63 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 32 Thousand | 70 Thousand | 84 Thousand | 593 Thousand | 33 Thousand | 382 Thousand |
| Change in working capital | 111 Thousand | 270 Thousand | -89 Thousand | 495 Thousand | 91 Thousand | -228 Thousand |
| Other non-cash items | - | - | 34 Thousand | 34 Thousand | - | - |
| Investing Cash Flow | - | -3000.00 | - | - | - | - |
| Investments in PPE | - | -3000.00 | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 690 Thousand | -61 Thousand | -52 Thousand | 5.77 Million | -60 Thousand | 1.84 Million |
| Debt repayment | -60 Thousand | -61 Thousand | -52 Thousand | -229 Thousand | -60 Thousand | -58 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 6 Million | - | 1.89 Million |
| Other Financing Activities | 750 Thousand | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 351 Thousand | 1.4 Million | 2.7 Million | 830 Thousand | 4.07 Million | 672 Thousand |
| Cash at end of period | 132 Thousand | 351 Thousand | 1.4 Million | 1.4 Million | 2.7 Million | 4.07 Million |
| Capital Expenditure | - | -3000.00 | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -219 Thousand | -1.05 Million | -1.3 Million | 573 Thousand | -1.36 Million | 3.39 Million |
| Free Cash Flow | -909 Thousand | -991 Thousand | -1.24 Million | -5.2 Million | -1.3 Million | 1.55 Million |
BAGFF
COLINZ
OMHI
HEVI
THNOF
002406